Specialties & Experience of this Expert Witness

Additional Information

Dr. Rouzbeh R. Taghizadeh has dedicated more than 20 years to bringing stem cell-based therapies to clinical practice. His expertise in adult stem cells, primarily human hematopoietic and mesenchymal stem cells—the regenerative cells involved in successful bone marrow and umbilical cord blood transplantations—uniquely positions him to approach science and business with the same keen powers of insight that have consistently reaped success surmounting scientific and medical barriers in the field. He earned his Ph.D. in Stem Cell Bioengineering in 2006 from the Massachusetts Institute of Technology (MIT) and co-founded AuxoCell Laboratories, Inc. as Chief Scientific Officer in 2008 after completing his post-doctoral training from MIT and the Boston Biomedical Research Institute. At MIT, in the laboratory of Dr. James L. Sherley, Dr. Taghizadeh focused on developing novel technologies to preferentially expand human hematopoietic stem cells ex vivo, a long-standing challenge faced by both researchers and clinicians. He separately worked towards the discovery of markers that exclusively identify human hematopoietic stem cells, a monumental feat in the field. Dr. Taghizadeh has contributed to numerous peer-reviewed publications, book chapters, and patents and is an editor of multiple books focused on Perinatal Stem Cells. Furthermore, Dr. Taghizadeh has presented at various international scientific conferences and industrial forums. Prior to obtaining his doctorate, Dr. Taghizadeh obtained his Bachelor of Science in Chemical Engineering from the University of Massachusetts, Amherst, in 2000. At AuxoCell, Dr. Taghizadeh developed novel methods and technologies in order to establish the collection, processing, and banking of stem cells from the human umbilical cord for eventual utilization in cell based therapies, regenerative medicine, and other clinical applications. Most notably, Dr. Taghizadeh and his team developed the patented AuxoCell Processing System (AC:Px®) in order to allow for standardized, efficient collection of stem cells from solid tissue in a closed, single-use, disposable system. Fusing business savvy with a laser focus on the clinical utility of stem cell-based therapies, Dr. Taghizadeh combines extensive stem cell industry expertise with his executive capacity to fully integrate business with science and engineering, in order to bring successful, novel therapies to patients.